Congratulations to Dr Deni Hardiansyah for winning the 1st Tomio Inoue Award at the 16th Asian and Oceanian Congress of Nuclear Medicine and Biology (AOCNMB). The work presented is based on a collaboration between the Ulm Medical Radiation Physics Group, the Department of Medical Physics and Biophysics at Universitas Indonesia and the Medical Physics Group at the Department of Nuclear Medicine at Freiburg University Hospital.
In the study entitled "Single-time-point kidneys and tumor absorbed dose calculation during [177Lu]Lu-PSMA-617 therapy using non-linear mixed-effects modeling", it was shown that a single SPECT/CT measurement 2 days after injection can predict the absorbed dose of kidneys and tumours during[177Lu]Lu-PSMA-617 therapy. The newly developed "STP-NLME" approach outperforms the commonly used simple STP method.
The Tomio Inoue Award is an honour given to scientists and researchers in the field of nuclear medicine who have made a significant contribution to the field. The award is named after Tomio Inoue, a leading figure in the field of nuclear medicine and biology, who is recognised for his scientific contributions to the development of medical imaging technology and nuclear medicine therapies.
The cooperation between the Ulm Medical Radiation Physics Group, the Department of Medical Physics and Biophysics at Universitas Indonesia and the Medical Physics Group at the Department of Nuclear Medicine at the University Hospital of Würzburg was honoured with the "International Best Abstract Award for Indonesia" for its contribution to the annual meeting of the American Society of Nuclear Medicine and Molecular Imaging (SNMMI).
The developed method optimises the accuracy and thus the reproducibility between different examiners. The resulting simplified dosimetry with only one measurement after 120 hours using the NLME method shows that it is acceptable and provides accurate values for thyroid therapy with 131I.
The cooperation between the Ulm Group for Medical Radiation Physics and the Department of Medical Physics and Biophysics at Universitas Indonesia was honoured with the "International Best Abstract Award for Indonesia" for its contribution to the annual meeting of the American Society for Nuclear Medicine and Molecular Imaging (SNMMI).
In molecular radiotherapy, an individual determination of time-integrated activities is required. The aim of this study was to develop an optimised, more reproducible method that combines non-linear mixed-effects modelling with population-based model selection for accurate determination of time-integrated activities. The technique was demonstrated using the example of renal dosimetry in 177Lu-PSMA therapy.
D. Hardiansyah, A. Riana, M. Eiber, A. J. Beer, G. Glatting, " Improving the accuracy of the time-integrated activity using non-linear mixed-effects modelling and population-based model selection in molecular radiotherapy," J Nuc Med 64, P519 (2023).
"FIRST PLACE POSTER - Molecular Targeting Probes".
The award-winning contribution presents the radiopharmaceutical production of an alpha emitter for clinical use.
Dirk Müller, Christoph Solbach, Mengshi Li, Dijie Liu, Ambros J. Beer, Michael Schultz, Vikas Prasad, "Radiopharmaceutical Production of [Pb-203]VMT-NET for Clinical Use" J Nucl Med 63, Suppl 2 (2022), Poster #2910.
The cooperation between the Ulm Medical Radiation Physics Group and the Department of Medical Physics and Biophysics at Universitas Indonesia was honoured with the "International Best Abstract Award for Indonesia" for its contribution to the annual meeting of the American Society of Nuclear Medicine and Molecular Imaging (SNMMI).
The award-winning paper explores ways to individualise nuclear medicine therapy using prior knowledge of the patient population.
D. Hardiansyah, A. Riana, P. Kletting, N. Zaid, A. Beer, G. Glatting, "Model Selection Based on Population Fitting at an Example of 177Lu-PSMAKinetics in Kidneys with a Low Number of Data," J Nuc Med 62, 1435-1435 (2021).
Optimisation of prostate cancer diagnostics
Trainee Research Prize of the Radiological Society of North America for Jonathan Miksch, resident in the Department of Nuclear Medicine
Jonathan Miksch, assistant physician in the Department of Nuclear Medicine, has been awarded the Trainee Research Prize at this year's annual meeting of the RSNA (Radiological Society of North America) for his submitted paper:
"[F-18]siPSMA-14 PET/CT Acquired at 90 Minutes p.i. Without Forced Diuresis Provides Optimal Contrast for Staging and Restaging of Prostate Cancer Patients". The prize is endowed with prize money of USD 1,000.
In recent years, diagnostics using radioactive substances whose target structure PSMA (prostate-specific membrane antigen) is found disproportionately frequently in prostate cancer cells has become established in nuclear medicine prostate cancer imaging. Mr Miksch's work presents the promising results of a new radioactive substance and its first clinical application in prostate cancer patients. [F-18]siPSMA-14 is a tracer that is comparatively easy to produce in large quantities and showed optimal conditions for tumour detection 90 minutes after injection, both in the initial diagnosis and in the recurrence situation.
The Radiological Society of North America is the world's largest association for radiologists, medical physicists and healthcare professionals.
Calculating the optimal tumour therapy
Award: Ulm medical physicist Dr Peter Kletting receives the Science Prize of the German Society for Medical Physics
The German Society for Medical Physics (DGMP) has honoured Dr biol. hum. Peter Kletting, medical physicist at the Department of Nuclear Medicine at Ulm University Hospital, with the Science Award 2020 for his research into the targeted irradiation of tumour tissue with radioactively labelled peptides.
You can read a detailed description of the research work here.
EMIM (ESMI) - Poster Award 2020
The Ulm Research Group for Preclinical Imaging, represented by Dr Gordon Winter, was honoured with the "Poster Award" for its contribution at the annual meeting (EMIM) of the European Society for Molecular Imaging (ESMI).
The award-winning work investigates the use of the chicken egg model as an alternative to animal experiments with mice in the development of new radiolabelled substances. The results of the studies have already been published.
Nusrat Begum, PhD student in the Department of Nuclear Medicine, was honoured with the Alavi Mandell Prize 2019
Nusrat Jihan Begum, MSc, PhD student in the Department of Nuclear Medicine at Ulm University Hospital, has been awarded the American Alavi Mandell Prize for her publication in The Journal of Nuclear Medicine (JNM, Impact Factor 7.4 (2017)). The prize was awarded for her publication entitled "The effect of total tumour volume on the biologically effective dose of tumour and kidney for 177Lu-labelledPSMA peptides".
Publication by Dr Peter Kletting, Department of Nuclear Medicine at Ulm University Hospital, was honoured by the German Society of Nuclear Medicine (DGN)
For his achievements in the field of nuclear medicine therapy, Dr biol. hum. Peter Kletting, a member of staff at the Department of Nuclear Medicine | Medical Radiation Physics at Ulm University Hospital , has been awarded this year's German Society of Nuclear Medicine (DGN) sponsorship prize for his achievements in the field of nuclear medicine therapy. The award is endowed with 3,000 euros. The prize is awarded to scientific publications that make an outstanding contribution to the establishment or optimisation of nuclear medicine therapies. Further information can be found in the press release.
Dr biol. hum. Peter Kletting (Ulm) has received one of the 3 Behnken-Berger Prizes 2017 for the development of a method to improve the therapeutic index for radioligand therapy. (Publication)
The award ceremony took place during the joint annual conference of the Biomedical Engineering and the three-country conference of Medical Physics on 11 September 2017 in Dresden.
Dr Peter Kletting's award-winning work describes a method that can be used to improve the therapeutic index for radioligand therapy.
With the help of the physiologically based pharmacokinetic model developed by Dr Kletting and the simulation algorithm, the combination of activity and amount of peptide used can be determined individually for each patient, which leads to the optimal ratio of biologically effective dose in the tumour to organs at risk. This increases the effectiveness of the therapy while the radiation exposure remains the same, or the radiation exposure of the organs at risk can be minimised for a given effect. The method developed can be transferred to other substances and is therefore extremely relevant for current and future therapy concepts. They therefore represent an important step in minimising the radiation exposure of patients. This outstanding work is closely related to the work previously published by Dr Kletting in the field of therapeutic use of ionising radiation.
The Ulm and Mannheim Medical Radiation Physics Group were honoured with the "International Best Abstract Award" for their contribution to the annual meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) in Denver, Colorado.
The award-winning paper examines ways to individualise nuclear medicine therapy. The results of the investigations have already been published.
By: Petra Schultze
Ulm medical physicists Dr Peter Kletting and Prof Dr Gerhard Glatting from the University Department of Nuclear Medicine have been awarded the prize for the best scientific article in the Journal of Medical Physics 2015.
Prof Dr Sven Norbert Reske receives the Georg von Hevesy Medal of the German Society of Nuclear Medicine
The German Society of Nuclear Medicine (DGN) has honoured Prof. Dr Sven Norbert Reske, Medical Director of the University Clinic for Nuclear Medicine in Ulm, with the Georg von Hevesy Medal. The award recognises Reske's achievements in establishing positron emission tomography (PET) in oncology and his contribution to leukaemia research and therapy in the field of radioimmunotherapy.
... [more]
By: Petra Schultze
Patients who have had thyroid cancer have the same risk of the disease recurring after successful treatment, regardless of the original prognosis. This was discovered by a team of nuclear medicine specialists in a long-term study. For their publication, the team of scientists from Würzburg, Ulm, Utrecht (NL), Leiden (NL) and Jersey City (USA) received the Brahms Research Prize for Thyroid Diseases 2010, endowed with 12,750 euros, at this year's annual conference of the German Society of Nuclear Medicine in Leipzig.
The German Society of Nuclear Medicine honours young scientist Peter Kletting from the Department of Nuclear Medicine with the Covidien Nuclear Medicine Award. [more]
Special recognition of the German Radiological Society in the category "Young Investigator Award" at the 90th German Radiological Congress 2009 for Mrs Nina Baier for her contributions:
- Somatostatin analogues in a colon carcinoid mouse model: comparison with FDG and 18F-DOPA
- PET of medullary thyroid carcinoma: Comparison of FDG, 18F-DOPAand 68Ga-DOTA-TOCin a mouse model.
By: Jörg Portius
Medical physicist Prof. Dr Glatting is honoured for his research by the German Society for Medical Physics on 13 September
The German Society for Medical Phys ics (DGMP) is honouring Ulm medical physicist Prof. Dr. Gerhard Glatting for his research into the targeted irradiation of tumour tissue with radioactively labelled antibodies in cancer patients. [more]
A.K. Buck, M. Bommer, M.E. Juweid, G. Glatting, S. Stilgenbauer, F.M. Mottaghy, M. Schulz, T. Kull, D. Bunjes, P. Möller, H. Döhner, S.N. Reske.
First Demonstration of Leukaemia Imaging with the Proliferation Marker 18F-Fluorodeoxythymidine.
J Nucl Med 49: 1756-1762, 2008 (IF=6.662).
Claudia Friesen from the University Clinic for Nuclear Medicine in Ulm received the Dietrich Schmähl Prize, endowed with 6,000 euros, in Freiburg on 16 June. [more]
C. Friesen, G. Glatting, B. Koop, K. Schwarz, A. Morgenstern, C. Apostolidis, K.-M. Debatin, S.N. Reske. Breaking chemo- and radioresistance with[213Bi]anti-CD45 antibodies in leukaemia cells.
Cancer Res 67(5): 1950-1958, 2007.
S.N. Reske, N.M. Blumstein, B. Neumaier, H.-W. Gottfried, F. Finsterbusch, D. Kocot, P. Möller, G. Glatting, S. Perner. Imaging prostate cancer with[11C]Choline PET/CT.
J Nucl Med 47(8): 1249-1254, 2006 (IF=4.684).
Buck AK, Halter G, Schirrmeister H, Kotzerke J, Wurziger I, Glatting G, Mattfeldt T, Neumaier B, Reske SN, Hetzel M: Imaging Proliferation in Lung Tumours with PET -[18F]FLT vs.[18F]FDG.
J Nucl Med 144: 1426-31, 2003.
Reske SN, Kotzerke J. FDG-PET for clinical use. Results of the 3rd German Interdisciplinary Consensus Conference, "Onko-PET III", 21 July and 19 September 2000. Eur J Nucl Med. 2001 28(11):1707-23.
Buck A, Schirrmeister HH, Guhlmann CA, Diederichs CG, Shen C, Buchmann I, Kotzerke J, Birk D, Mattfeldt T, Reske SN. Ki-67 immunostaining in pancreatic cancer and chronic active pancreatitis: does in vivo FDG uptake correlate with proliferative activity? J Nucl Med. 2001 May;42(5):721-5.
Schirrmeister H, Kühn T, Guhlmann A, Santjohanser C, Hörster T, Nüssle K, Koretz K, Glatting G, Rieber A, Buck A, Reske SN: [F-18] 2-deoxy-2-fluoro D-glucose PET in preoperative staging of breast cancer - comparison with the standard imaging procedures.
Eur J Nucl Med 28: 351-358, 2001.
Helax Prize 1998 for the best lecture "Computer Applications in Medical Physics" on the topic: "Non-invasive calculation of cerebral blood flow from O-15 water PET data" by Dr Gerhard Glatting
Editor's Excellence Awards for Outstanding Scientific Research 1996 of the "Journal of Computer Assisted Tomography" for the article
C.G. Diederichs, D.P. Keating, G. Glatting, J.W. Oestmann. Blurring of Vessels in Spiral CT Angiography: Effects of Collimation Width, Pitch, Viewing Plane, and Windowing in Maximum Intensity Projection. J Comput Assist Tomogr 20(6): 965-974, 1996.